Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Symlin And Byetta Excluded From American Diabetes Association Guideline

Executive Summary

Amylin's Symlin and Byetta are among several products excluded from a recommended treatment guideline for type 2 diabetes from the American Diabetes Association

You may also be interested in...



Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products

Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market

Mid-Cap Biotechs Rise In ’06; Small Firms Face “Burden” Of New Products

Disappointing product launches by CV Therapeutics and NitroMed underscore the challenges that small manufacturers face in trying to successfully bring new products to market

GSK Pushing For ADOPTion Of Avandia For First-Line Type 2 Diabetes Therapy

GlaxoSmithKline plans to use the results of its ADOPT study to establish its thiazolidinedioneAvandia as the standard first-line treatment for type 2 diabetes

Related Content

UsernamePublicRestriction

Register

PS047525

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel